NewsBenzingaRBC 캐피털, 비리디언 테라퓨틱스에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 38달러로 상향 RBC 캐피털, 비리디언 테라퓨틱스에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 38달러로 상향 Benzinga 2026.09.22 13:32 (GMT+0) Open on Benzinga Other news RBC Is Bullish on Kraft Heinz Stock and Expects Growth to Return in 2027 Huawei Is Ramping Up to New Chips in 2027. What That Means for Nvidia Stock Now. AstroForge is putting AI in command of its next spacecraft Five AI safety sessions every founder should have on their TechCrunch Disrupt 2026 agenda Meta’s Muse Is Dominating the App Store. What This Means for META Stock. Deutsche Bank Maintains Hold on Endava, Lowers Price Target to $2
